Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xilio Therapeutics (XLO) Non Operating Income (2024 - 2025)

Historic Non Operating Income for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to -$14.4 million.

  • Xilio Therapeutics' Non Operating Income fell 203504.04% to -$14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.7 million, marking a year-over-year change of. This contributed to the annual value of $2.3 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Xilio Therapeutics reported Non Operating Income of -$14.4 million as of Q3 2025, which was down 203504.04% from -$1.5 million recorded in Q2 2025.
  • In the past 5 years, Xilio Therapeutics' Non Operating Income registered a high of $779000.0 during Q2 2024, and its lowest value of -$14.4 million during Q3 2025.